We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Catalyst Pharmaceuticals has settled with Jacobus Pharmaceutical over claims that Jacobus’ Lambert-Eaton myasthenic syndrome (LEMS) drug Ruzurgi (amifampridine) infringed on its patent rights for Firdapse (amifampridine). Read More
Zynlonta was granted FDA accelerated approval in April 2021 as a single-agent intravenous treatment for adult patients with relapsed or refractory DLBCL after two or more lines of systemic therapy. Read More
Bristol Myers Squibb (BMS) has settled with Alembic Pharmaceuticals over allegations that Alembic’s proposed generic drug infringed on its blockbuster blood cancer drug Revlimid (lenalidomide). Read More
AstraZeneca is buying TBio subsidiary TeneoTwo, which will shore up its hematology pipeline with TeneoTwo’s candidate for relapsed and refractory B-cell non-Hodgkin lymphoma. Read More